Lupin Limited announced a record quarter for Q1 FY27, with total revenues and EBITDA exceeding INR 8,000 crore and INR 2,400 crore respectively. This marks the 16th consecutive quarter of year-over-year growth. The company highlighted strong ex-U.S. organic growth of over 20%, driven by its diversified business model and operational excellence. Key markets like India, Other Developed Markets, and Emerging Markets showed robust performance, with new product launches and strategic initiatives expected to drive future growth.
Lupin Reports Record Q1 FY27 Performance
Lupin Limited has announced a landmark first quarter for FY27, achieving record financial results. Total revenues from operations reached INR 8,277 crore, a significant 32% increase year-over-year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA), excluding forex and other income, grew by a strong 50% to INR 2,464 crore. This performance marks the company’s 16th consecutive quarter of year-over-year growth, underscoring sustained positive momentum.
Geographical Growth Drivers
The company’s growth was notably broad-based across its key geographies. The U.S. business saw a 43% year-over-year increase in sales. India’s prescription business grew by 15.1%, outpacing the market growth. Other Developed Markets, including Europe, Canada, and Australia, experienced a 48% surge, contributing 14% to total sales. Emerging markets delivered an impressive 52% year-over-year growth, spearheaded by strong performance in Brazil, South Africa, and the Philippines.
Strategic Focus and Future Outlook
Lupin highlighted its continued focus on operational excellence and strategic market penetration. The company is emphasizing growth in complex products, including respiratory, injectables, and biosimilars, particularly in the U.S. Future strategies involve launching over 50 products in the U.S. over the next three years, with a significant number of exclusive first-to-files and biosimilars. The company reaffirms its guidance of high single-digit revenue growth for the full year and expects EBITDA margins to be around 25%.
Key Product Pipeline and R&D
R&D spend for the quarter stood at 7.4% of sales, with a focus on complex and specialty platforms. Over 50 active products are in the pipeline, with near-term emphasis on respiratory, complex injectables, and biosimilars. The company also noted progress on its 505(b)(2) pipeline, with product launches expected to contribute significantly from FY28 onwards. Innovation in India is also a key focus, with plans to contribute one-third of India’s revenues from proprietary products over the next decade.
Financial Highlights
Gross margins improved to 74.6%, up from 71.3% in the prior year, driven by a better product mix, higher profitability, and cost efficiencies. Employee benefit expenses increased by 28% YoY. Manufacturing and other expenses represented 28.5% of sales. Depreciation and amortization increased due to higher amortization of settlement agreements. The effective tax rate for the quarter was 29.8%, with a full-year expectation between 27% – 28%.
Source: BSE
